PYRUKYND, a pyruvate kinase activator, remains the flagship product with multi-billion-dollar potential. Agios is targeting a U.S. approval for thalassemia by September 7, 2025, and a sickle cell ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported business highlights and financial ...

Punjab Information Minister Azma Bokhari visited Sundas Foundation in Lahore, where she spent time with children battling ...

Ranchi: The health department of the Ranchi district has introduced advanced testing facilities for genetic blood disorders, ...

India handed over Sickle Cell and Thalassemia vaccines to Nepal in response to the Nepal government’s request, a statement ...

As per the release from the Indian Embassy in Kathmandu the first consignment of vaccines is worth USD 2 million. It would be for the management of patients with Thalassemia and Sickle Cell Disease ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

Thalassemia and sickle cell anaemia are common genetic disorders in India. Early testing, prenatal screening, and improved ...

Oral infections are more likely to occur in people with chronic kidney disease and are more likely to become a significant problem. Proper dental care also benefits people on dialysis or those ...

The following is a summary of “Assessment of ferritin and hepcidin levels in splenectomised and non-splenectomised β-thalassemia major patients and exploring a potential correlation with von ...